(Ivanhoe Newswire) -- Organ transplants can save lives, but new research
shows they might also put recipients at risk of developing cancer.
New research at the Harvard Medical School revealed the immunosuppressive drug
cyclosporine ramps up vascular endothelial growth factor (VEGF), causing new
blood vessels to grow and feed tumors. Tumors that develop after a transplant
can come from three sources: viruses from the organ donor, pre-existing cancer
or recurrence of previous cancer.
The study revealed a potential treatment: anti-VEGF therapy, which could inhibit
cancerous cell growth. For the 15 to 20 percent of patients who develop cancer
in the decade that they received transplants, this could be great news.
Researchers found the anti-VEGF therapy drastically reduced tumor growth in mice
implanted with human kidney cancer cells.
VEGF expression is necessary in the immediate stage after transplantation, but
after organ stabilization, lowering VEGF expression is important to “prevent
tumor growth and keep cancer at bay,” Soumitro Pal, Ph.D., an assistant
professor at Harvard Medical School’s Transplantation Research Center at
Children’s Hospital in Boston, was quoted as saying. He added, “We would need to
figure out how to balance benefit and risk to keep cancer at bay.”
SOURCE: Cancer Research, 2008;68,5689-5698
